Catalyst Biosciences Dividend

Dividend criteria checks 0/6

Catalyst Biosciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$17.47
Dividend yield forecast in 3Y	n/a

Recent dividend updates

Recent updates

Shareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why

Jun 03

Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely

May 18

Catalyst Biosciences EPS misses by $0.12, beats on revenue

May 06

Would Shareholders Who Purchased Catalyst Biosciences' (NASDAQ:CBIO) Stock Five Years Be Happy With The Share price Today?

Mar 09

We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely

Feb 01

Catalyst Biosciences announces closing of $50M capital raise

Jan 29

Do Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?

Dec 28

Catalyst Biosciences' MarzAA fast track'd for episodic bleeding in hemophilia patients

Dec 02

What We Learned About Catalyst Biosciences' (NASDAQ:CBIO) CEO Pay

Dec 02

Catalyst Biosciences (CBIO) Presents At Stifel 2020 Virtual Healthcare Conference - Slideshow

Nov 18

Catalyst Biosciences: After 2 Fundraisings, A Lengthy Wait For Pivotal Trial Data Is Next

Nov 14

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if CBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBIO's dividend payments have been increasing.

Dividend Yield vs Market

Catalyst Biosciences Dividend Yield vs Market

How does CBIO dividend yield compare to the market?
Segment	Dividend Yield
Company (CBIO)	n/a
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.9%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (CBIO)	n/a

Notable Dividend: Unable to evaluate CBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate CBIO's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CBIO has not reported any payouts.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Catalyst Biosciences Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Inaugural dividend of US$0.24 per share

Catalyst Biosciences, Inc. Declares Special One-Time Cash Dividend, Payable on September 20, 2022

Recent updates

Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. (NasdaqCM:CBIO) in a reverse merger transaction.

Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.

Catalyst Biosciences Announces Update on Letter from Nasdaq Regarding Minimum Bid Price Requirement

Full year 2022 earnings: EPS misses analyst expectations

Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer

Inaugural dividend of US$0.24 per share

Insufficient new directors

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)

Catalyst Biosciences Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Insider recently sold US$284k worth of stock

Insider recently sold US$506k worth of stock

Catalyst Biosciences, Inc. Declares Special One-Time Cash Dividend, Payable on September 20, 2022

Catalyst Biosciences declares special one-time dividend of $1.43

Catalyst Biosciences, Inc. Announces Dismissal of Jds1 Litigation

Second quarter 2022 earnings released: EPS: US$1.64 (vs US$0.64 loss in 2Q 2021)

Forecast to breakeven in 2022

Catalyst Biosciences: Shareholders Should Reap Benefits From Owning The Stock

JEC II Associates, LLC Reaches an Agreement Catalyst Biosciences

JDS1 LLC Issues an Investor Presentation to Shareholders of Catalyst Biosciences Inc

JDS1, LLC Provides Information to the Shareholders

Catalyst Biosciences plans to distribute $65M cash to stockholders

Insider recently bought US$936k worth of stock

JEC II Associates Engages in Discussions with Catalyst Biosciences

JDS1, LLC Provides Information to the Shareholders

Catalyst Biosciences, Inc., Annual General Meeting, Aug 15, 2022

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

Consensus revenue estimates fall by 86%

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

Consensus revenue estimates increase by 16%

First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.79 loss in 1Q 2021)

Price target decreased to US$3.00

JDS1 Files a Complaint against Catalyst Biosciences

JDS1 Provides Information to Shareholders of Catalyst Biosciences

Consensus forecasts updated

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian Singer Sends Letter to Catalyst Biosciences

Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency

Companies Like Catalyst Biosciences (NASDAQ:CBIO) Could Be Quite Risky

Circling Back On Catalyst Biosciences

Third quarter 2021 earnings released: US$0.80 loss per share (vs US$0.73 loss in 3Q 2020)

Price target decreased to US$13.25

FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.96 loss in 2Q 2020)

Consensus revenue estimates increase to US$4.10m

Catalyst Biosciences Announces First Patient Screened for CFI Deficiency in Its CB 4332 Screening and Natural History of Disease Studies

Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from Russell 3000E Value Index

Shareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why

Catalyst Biosciences, Inc. Announces Initiation of Dosing in the Company's Phase 1/2 Study (MAA-202) of Marzeptacog Alfa

Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely

Consensus forecasts updated

Catalyst Biosciences Announces the Dosing of the First Patient in the Crimson 1 Study, the Company's Phase 3 Registration Trial (Maa-304 - Crimson 1)

Catalyst Biosciences EPS misses by $0.12, beats on revenue

Would Shareholders Who Purchased Catalyst Biosciences' (NASDAQ:CBIO) Stock Five Years Be Happy With The Share price Today?

Revenue and earnings beat expectations

Price target lowered to US$17.00

Price target lowered to US$18.00

Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress

We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely

Catalyst Biosciences announces closing of $50M capital raise

Do Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?

New 90-day high: US$7.29

Catalyst Biosciences, Inc. Receives FDA Fast Track Designation for Subcutaneous Marzaa for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors

Catalyst Biosciences' MarzAA fast track'd for episodic bleeding in hemophilia patients

What We Learned About Catalyst Biosciences' (NASDAQ:CBIO) CEO Pay

Catalyst Biosciences (CBIO) Presents At Stifel 2020 Virtual Healthcare Conference - Slideshow

Catalyst Biosciences: After 2 Fundraisings, A Lengthy Wait For Pivotal Trial Data Is Next

Earnings miss expectations

New 90-day high: US$6.41